With multiple first-time clinical data readouts due this year, some of which – in the view of Raymond James analyst Reni Benjamin – could "transform the company," immuno-oncology (I-O) player Leap Therapeutics Inc. is readying for the first round at the American Association of Cancer Research (AACR) meeting in Chicago starting Saturday.